Money
DAFNA Capital Adjusts iShares Biotechnology ETF Holdings in Strategic Portfolio Shift
DAFNA Capital's recent SEC filing indicates a recalibration of its iShares Biotechnology ETF holdings, reflecting a broader strategic adjustment in its biotech investments.
Editorial Staff
1 min read
On March 21, 2026, DAFNA Capital filed with the SEC, detailing modifications to its holdings in the iShares Biotechnology ETF.
These adjustments are part of a larger strategy aimed at optimizing their biotech portfolio.
The iShares Biotechnology ETF continues to play a significant role in DAFNA's investment framework, despite the recent changes.